Chemotherapy and Radiation for Stomach Cancer
Author Information
Author(s): Leong T, Michael M, Foo K, Thompson A, Joon D Lim, Weih L, Ngan S, Thomas R, Zalcberg J
Primary Institution: Peter MacCallum Cancer Centre
Hypothesis
Can a new chemotherapy regimen improve outcomes for gastric cancer patients undergoing chemoradiation?
Conclusion
The study suggests that using ECF chemotherapy before and after chemoradiation can be delivered safely with acceptable toxicity.
Supporting Evidence
- Patients treated with ECF had a 1-year relapse-free survival rate of 87%.
- The overall rate of grade 3 toxicity was 38%.
- Continuous infusion 5-FU during radiation is less toxic and better tolerated.
Takeaway
Doctors are trying a new combination of medicines to help people with stomach cancer feel better after surgery. They found that this new way is safer and has fewer side effects.
Methodology
Patients with gastric cancer received a new chemotherapy regimen (ECF) before and after chemoradiation, and their outcomes were monitored for toxicity and feasibility.
Limitations
The short follow-up period limits the analysis of long-term relapse and survival patterns.
Participant Demographics
{"age":{"median":60,"range":"34-82"},"sex":{"male":21,"female":5}}
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website